JP2017537622A5 - - Google Patents

Download PDF

Info

Publication number
JP2017537622A5
JP2017537622A5 JP2017529284A JP2017529284A JP2017537622A5 JP 2017537622 A5 JP2017537622 A5 JP 2017537622A5 JP 2017529284 A JP2017529284 A JP 2017529284A JP 2017529284 A JP2017529284 A JP 2017529284A JP 2017537622 A5 JP2017537622 A5 JP 2017537622A5
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
acid sequence
domain
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017529284A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537622A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/063267 external-priority patent/WO2016089916A1/en
Publication of JP2017537622A publication Critical patent/JP2017537622A/ja
Publication of JP2017537622A5 publication Critical patent/JP2017537622A5/ja
Pending legal-status Critical Current

Links

JP2017529284A 2014-12-02 2015-12-01 がんを治療するための方法及び組成物 Pending JP2017537622A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086346P 2014-12-02 2014-12-02
US62/086,346 2014-12-02
PCT/US2015/063267 WO2016089916A1 (en) 2014-12-02 2015-12-01 Methods and compositons for treating cancer

Publications (2)

Publication Number Publication Date
JP2017537622A JP2017537622A (ja) 2017-12-21
JP2017537622A5 true JP2017537622A5 (OSRAM) 2019-01-10

Family

ID=56078487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017529284A Pending JP2017537622A (ja) 2014-12-02 2015-12-01 がんを治療するための方法及び組成物

Country Status (18)

Country Link
US (2) US9650428B2 (OSRAM)
EP (1) EP3227317A4 (OSRAM)
JP (1) JP2017537622A (OSRAM)
KR (1) KR20180041087A (OSRAM)
CN (1) CN107709353A (OSRAM)
AR (1) AR102879A1 (OSRAM)
AU (1) AU2015355084A1 (OSRAM)
BR (1) BR112017011771A2 (OSRAM)
CA (1) CA2969714A1 (OSRAM)
EA (1) EA201791210A1 (OSRAM)
HK (1) HK1251862A1 (OSRAM)
IL (1) IL252610A0 (OSRAM)
MX (1) MX2017007272A (OSRAM)
PH (1) PH12017501031A1 (OSRAM)
SG (2) SG11201704519YA (OSRAM)
TW (1) TW201636425A (OSRAM)
UY (1) UY36418A (OSRAM)
WO (1) WO2016089916A1 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2850093B1 (en) 2012-01-27 2019-01-09 The Board of Trustees of the Leland Stanford Junior University Therapeutic il-13 polypeptides
US9738696B2 (en) 2012-08-09 2017-08-22 The Board Of Trustees Of The Leland Stanford Junior University Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities
US20150320799A1 (en) 2012-12-20 2015-11-12 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
WO2015042705A1 (en) 2013-09-24 2015-04-02 Medicenna Biopharma Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
SG11201704519YA (en) 2014-12-02 2017-07-28 Roger Williams Hospital Methods and compositons for treating cancer
DK3310805T3 (da) * 2015-06-19 2021-05-03 Sebastian Kobold Pd-1-cd28-fusionsproteiner og anvendelse deraf i medicin
KR102011789B1 (ko) * 2015-08-05 2019-08-19 주식회사 셀랩메드 키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
US20200095301A1 (en) * 2016-12-14 2020-03-26 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
EP3589295B1 (en) 2017-02-28 2024-09-11 Endocyte, Inc. Compositions and methods for car t cell therapy
AU2018256436B2 (en) 2017-04-19 2024-12-05 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
AU2018347796B2 (en) 2017-10-10 2025-07-24 Medicenna Therapeutics, Inc. IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
CN111629736A (zh) * 2017-11-20 2020-09-04 罗杰威廉姆斯医疗中心以普拉斯派克特查特凯尔Rwmc有限责任公司许可 用于改善car-t细胞功能的组合物及其用途
WO2019126574A1 (en) * 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Vcar compositions and methods for use
CA3089319A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
US11701405B2 (en) * 2018-01-26 2023-07-18 City Of Hope Chimeric antigen receptors and methods for reducing toxicity
US12312416B2 (en) 2018-02-06 2025-05-27 Seattle Children's Hospital Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
CN110157674A (zh) * 2018-02-12 2019-08-23 深圳宾德生物技术有限公司 一种靶向性t淋巴细胞及其制备方法和应用
CN110144326A (zh) * 2018-02-12 2019-08-20 深圳宾德生物技术有限公司 一种靶向性抗肿瘤t细胞及其制备方法和应用
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Car t細胞療法のための配列決定法
CN108440674A (zh) * 2018-04-28 2018-08-24 杭州荣泽生物科技有限公司 一种Trop-2特异性嵌合抗原受体细胞制备及其用途
US12404497B2 (en) 2018-06-01 2025-09-02 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof
JP2023512250A (ja) * 2020-01-31 2023-03-24 シティ・オブ・ホープ IL13Rα2陽性悪性腫瘍の治療のための標的キメラ抗原受容体修飾T細胞
EP4159237A4 (en) * 2020-05-28 2024-08-28 Chugai Seiyaku Kabushiki Kaisha Improved granzyme b variant
CN116348482A (zh) * 2020-08-26 2023-06-27 加利福尼亚大学董事会 用于治疗胶质母细胞瘤的方法和组合物
BR112023004433A2 (pt) * 2020-09-11 2023-04-11 Univ Georgia Ácido nucleico, vetor, segmento genômico viral, vírus, composição farmacêutica, método para induzir ou aumentar uma resposta imune contra o vírus influenza, vírus recombinante, método para induzir uma resposta imune em um sujeito em necessidade e polipeptídeo
CA3202218A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CN114907485B (zh) * 2021-02-08 2024-04-26 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
CN113304267B (zh) * 2021-06-11 2022-03-15 河南大学 肺癌的治疗靶点及其应用
CN114014941B (zh) * 2022-01-10 2022-04-12 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的嵌合抗原受体及其用途
CN116549667B (zh) * 2023-05-29 2024-02-09 四川普锐特药业有限公司 一种pas修饰的脂质纳米粒、包含其的药物制剂,及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965126A (en) * 1996-03-25 1999-10-12 The Penn State Research Foundation use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
EP1222289B1 (en) * 1999-10-20 2008-04-16 The Johns Hopkins University School Of Medicine Chimeric immunogenic compositions and nucleic acids encoding them
WO2003073841A2 (en) * 2002-03-01 2003-09-12 Bristol-Myers Squibb Company Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
WO2003086451A1 (en) * 2002-04-05 2003-10-23 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
US7709625B2 (en) * 2004-06-10 2010-05-04 The Board Of Regents Of The University Of Texas Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy
AU2005339587B2 (en) * 2005-11-16 2011-11-03 Universidad Nacional Autonoma De Mexico Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer
CN101616685B (zh) * 2006-03-06 2013-07-24 阿穆尼克斯运营公司 非结构化重组聚合物和其应用
US20080206139A1 (en) * 2006-11-03 2008-08-28 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
ES2961498T3 (es) * 2008-08-26 2024-03-12 Hope City Método y composiciones para el funcionamiento mejorado del efecto antitumoral de las células T
US9273283B2 (en) * 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
CA3188287C (en) * 2010-03-26 2025-07-08 Memorial Sloan-Kettering Cancer Center MUC16 ANTIBODIES AND METHODS OF USE
EP2931893A1 (en) * 2012-12-13 2015-10-21 Universität Leipzig T-cell modulation by exon skipping
KR102332790B1 (ko) * 2013-02-15 2021-12-01 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키메라 항원 수용체 및 이의 이용 방법
WO2014164554A1 (en) * 2013-03-10 2014-10-09 Baylor College Of Medicine Chemotherapy-resistant immune cells
ES2792849T3 (es) * 2014-02-10 2020-11-12 Univ Emory Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
SG11201704519YA (en) 2014-12-02 2017-07-28 Roger Williams Hospital Methods and compositons for treating cancer

Similar Documents

Publication Publication Date Title
JP2017537622A5 (OSRAM)
Heidbuechel et al. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies
JP2022109953A5 (OSRAM)
JP2018529380A5 (OSRAM)
JP2023139070A5 (OSRAM)
JP6919091B2 (ja) Gタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用
JP2017537627A5 (OSRAM)
JP2018516092A5 (OSRAM)
JP2020529841A5 (OSRAM)
JP2019535262A5 (OSRAM)
JP2017538401A5 (OSRAM)
JP2019500894A5 (OSRAM)
HRP20190472T1 (hr) Klaudin-6 specifični imunoreceptori i t-stanični epitopi
JP2018518459A5 (OSRAM)
JP2017500869A5 (OSRAM)
JP2016534717A5 (OSRAM)
JP2018513687A5 (OSRAM)
JP2017526361A5 (OSRAM)
JP2016519068A5 (OSRAM)
JP2017529067A5 (OSRAM)
JP2020513754A5 (OSRAM)
JP2018505139A5 (OSRAM)
CN108137670A (zh) Ny-eso-1特异性tcr及其使用方法
RU2016124278A (ru) Клетка
JP2015518479A5 (OSRAM)